Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
Date:3/6/2012

ls of Oncology. 2010: 5: 172-174.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of CTI's drug candidates include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory aggressive NHL and/or other tumors as determined by the FDA and/or the EMA, that Pixuvri may not be the first drug approved as monotherapy for the treatment of adult patients with multiple relapsed or refractory aggressive NHL, that the European Commission may not formally adopt the CHMP's recommendation regarding Pixuvri, that conditional approval of CTI's MAA for Pixuvri may not be granted by the European Commission within the next few months or at all, that Pixuvri may not be approved for marketing in all of the E.U. Member States and the European Economic Area members, that the EMA may request additional information from CTI regarding Pixuvri, the potential failure of tosedostat to prove safe and effective for the treatment of relapsed MDS, AML, multiple myeloma, blood related cancers and solid tumors as determined by the FDA and/or the EMA, that the FDA may not accept the proposed clinical trial of tosedostat and/or may request additional trials, that CTI may not meet with the FDA in March 2012 regarding the phase 3 clinical trial of tosedostat in MDS, that CTI may not acquire any additional novel clinical stage compounds to expand its hematologic cancer product pipeline, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI may not
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
2. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
3. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
4. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO Investor Forum
5. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
6. Reed V. Tuckson, M.D., Executive Vice President and Chief of Medical Affairs at UnitedHealth Group, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Intrinsic Therapeutics, Inc. Names Cary P. Hagan as President & CEO
8. Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
9. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
10. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
11. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... addition of Kent Hance , the former chancellor of ... Hance retired as chancellor in July 2014, after raising $1.2 ... announce that Kent Hance , the most successful chancellor ... Kiromic team not only as an investor, but also as ...
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... Sept. 19, 2014  4WEB Medical announces the formal ... and ankle osteotomy implants on the market today ... annual meeting in Chicago .  The ... a surgeon,s osteotomy needs with 74 size options included in ... offerings of only 15 to 18 implant sizes, which ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at the Deutsche Bank 36th Annual ... presentation takes place on Wednesday, May 4, 2011 at 10:40 ... will be webcast and may be accessed on the Company,s ...
... Inc. (Nasdaq: AMLN ) will be presenting at ... Wednesday, May 4, 2011 at 12:15 p.m. ET / 9:15 ... and chief financial officer at Amylin Pharmaceuticals, will provide a ... through the "Investors" section of Amylin,s corporate website at ...
Cached Medicine Technology:
(Date:9/19/2014)... 2014 Unbound , an international humanitarian ... regions of the Philippines being affected by both a tropical ... families evacuated to the nearest public schools while others moved ... and gusty winds to portions of the northern Philippines. ... homes filled with more than 10 feet of water. ...
(Date:9/19/2014)... On September 16, Camino Public Relations ... and Top Places to Work in PR Awards Luncheon ... received honorable mentions in two categories for “Multicultural Campaign” ... elevating Latina voices in the media. , "We're honored ... part of its efforts to improve the national conversation ...
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... 19, 2014 Boston Scientific Corp. has ... ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled to go ... Liebhard LLP reports. According to a Motion ... company asserts that claims involving its Solyx pelvic mesh ... Remedies Code, a section of which shields manufacturers ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Pregnant women who ... premature or low birth weight babies, a new study suggests. ... Vancouver, Canada, and found that expectant mothers who lived in ... had a 20 percent lower risk of very preterm birth ... moderate preterm birth (30 to 36 weeks). Babies born ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Melanoma risk found to have genetic determinant 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Do Greener Neighborhoods Produce Healthier Babies? 2
... , SANTA ROSA, Calif., Sept. 21 Osseon ... cement delivery needle) and Osseoflex DR (steerable and curvable bone ... for marketing and clinical use in the European Union. , ... FDA approval in the United States, and allows for the ...
... , PEMBROKE, Bermuda, Sept. 21 ... announced today that Linda,McSmith, AVP, Risk Management for Allied World ... Allied World, at the Ohio Association of,Ambulatory Surgery Centers (OAASC) ... September 24-25, 2009. , Ms. McSmith,s ...
... , , , ... Inc. ("Astellas"), in partnership with the National Science Teachers Association ... science teachers to participate in the 2009 NSTA New Science ... to a range of tools and resources, while providing the ...
... , , PHILADELPHIA and LONDON, Sept. 21 ... that provides a unique combination of competitive intelligence and sales forecast ... of pipeline and marketed drugs . The product will be ... on October 8 and 9, and Bio Europe 2009 in Vienna ...
... N.C. The Defense Advanced Research Projects Agency (DARPA), the ... Duke University $19.5 million for an effort led by the ... a portable, easy-to-use diagnostic device that can reveal who is ... or sneeze. DARPA is interested in such a ...
... research and real world operation of electronic medical ... have developed, tested and are now operating innovative ... evidence-based medical information between clinical sources and public ... new tools developed by the Regenstrief Institute that ...
Cached Medicine News:Health News:Osseon Receives CE Mark 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 3Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 2Health News:Astellas and The National Science Teachers Association Announce 2009 Class of Local Science Educators 3Health News:Thomson Reuters Launches Thomson Pharma Partnering Forecast 2Health News:DARPA awards Duke $19.5 million to detect viral infection before symptoms appear 2Health News:Fighting disease outbreaks with 2-way health information exchange 2
ROB-NEL Catheters (100% Latex-Free)...
Red Rubber Robinson Catheters (Latex)...
Urethral Red Rubber Catheters (Latex)...
Foley Catheters (Latex) 3-Way...
Medicine Products: